India Pharma – Non Covid-19 Portfolio Dominates Contribution For IPM Growth In August: Prabhudas Lilladher

Today News ||

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Prabhudas Lilladher Report

Indian pharma market is gradually gaining ground around core products, as non-Covid-19 portfolio led August 2021 growth.

We expect encouraging trend to continue as Covid cases remain low with more than 50% of total adult population vaccinated (at least one dose of vaccine).


Low spread of Covid wave – three will augur well for IPM to maintain healthy growth of its core portfolio in H2 FY22E.

The growth trend of parameters like volume, value and new products of IPM were highly balanced in Aug 2021, which again indicates normalisation in the industry.

Click on the attachment to read the full report:

Prabhudas Lilladher Pharma Sector – August IPM.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

More Economy Business News Updates of Today Check Below

Today News || Business Today || World News || Headlines Today || Health || Technology News || Education News


Show More

Related Articles

Back to top button